Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1648 1671 1672
This examiner grants 74% of resolved cases
Barry A Chestnut is an examiner in Tech Center 1600 and Art Unit 1637, with 750 resolved cases to their credit. The data reveals an allowance rate of 73.5%, establishing a clear success rate for practitioners. The interview lift of 6.4% indicates that interviews provide a modest increase in the probability of allowance over the 73.5% baseline. This suggests that while interviews are beneficial, the overall allowance rate is driven by the substantive merits of the applications.
The median days to allowance is 991, reflecting the typical time investment required to secure a patent with this examiner. Across 750 resolved cases, this 991-day metric remains a stable expectation for Art Unit 1637. While the 6.4% interview lift offers a slight improvement, the primary focus for attorneys should be on the 73.5% allowance rate. Practitioners can use the 991-day median to manage client expectations in Tech Center 1600. The examiner's history provides a consistent data set for strategic planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18573582 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Non-Final OA | DYNO THERAPEUTICS, INC. |
| 18827183 | SELF-REPLICATING RNA AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 18769900 | SCALABLE CHROMATOGRAPHY PROCESS FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18701156 | MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE | Non-Final OA | The Cleveland Clinic Foundation |
| 18480009 | USE AND DETECTION METHOD OF FLAVIVIRUS PROTEIN MICROARRAY | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18794860 | FELINE LEUKEMIA VIRUS VACCINE | Non-Final OA | INTERVET INC. |
| 18683835 | METHOD OF PRODUCING A FOOT AND MOUTH DISEASE VIRUS VIRUS-LIKE PARTICLE | Non-Final OA | Intervet Inc. |
| 18699032 | INFLUENZA VACCINES | Non-Final OA | Cambridge Enterprise Limited |
| 18744397 | Method of Generating Phage Clones with Expanded Activity | Non-Final OA | The Government of the United States, as Represented by The Secretary of The Army |
| 18711073 | SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES | Non-Final OA | CITY OF HOPE |
| 18713100 | IMPROVED ISOTHERMAL AMPLIFICATION | Non-Final OA | GENETIC SIGNATURES LIMITED |
| 18658604 | SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Gritstone bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy